| GOG-0286B | A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer | Terminated | II/III | >Gynecologic [GY] | Uterine Corpus |
| GOG-0278 | Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (</= 2 cm) Cervical Cancer | Terminated | I/II | >Gynecologic [GY] | Cervix |
| GOG-0264 | A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary. | Terminated | II | >Gynecologic [GY] | Ovarian |
| NRGF-001 | Activity Monitoring To Improve Patient Care During Chemoradiotherapy For Locally Advanced Non-small Cell Lung Cancer (La-nsclc)
| Terminated | I | >Lung [LU] | Non-small Cell Lung Cancer |
| NRG-BN009 | Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity ≥4 Brain Metastases/Year
| Terminated | III | >Brain [BN] | Other |
| GOG-0274 RTOG 1174 | A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL | Terminated | III | >Gynecologic [GY] | Cervix |
| GOG-0279 | A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva | Terminated | II | >Gynecologic [GY] | Other |
| GOG-0238 | A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus | Terminated | II | >Gynecologic [GY] | Uterine Corpus |
| NRG-GY016 | A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary | Terminated | II | >Gynecologic [GY] | Ovarian |
| NRG-HN007 | An Open Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | Terminated | III | >Head and Neck [HN] | Head and Neck |
| RTOG-0926 | A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging | Terminated | II | >Genitourinary [GU] | Bladder |
| RTOG-0539 | Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas | Terminated | II | >Brain [BN] | Other |
| RTOG-1010 | A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma | Terminated | III | >Gastrointestinal [GI] | Esophageal |
| NRG-BN002 | Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma | Terminated | I | >Brain [BN] | Malignant Glioma |
| RTOG-0232 | A Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic Carcinoma | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-0415 | A Phase III Randomized Study of Hypofractionated 3DCRT/IMRT versus Conventionally Fractionated 3DCRT/IMRT in Patients Treated for Favorable-Risk Prostate Cancer | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-0126 | A Phase III Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients Treated for Localized Prostate Cancer | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-1205 | Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma | Terminated | II | >Brain [BN] | Other |
| RTOG-1119 | Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG | Terminated | II | >Breast [BR] | Breast |
| RTOG-1106 | RTOG 1106/ACRIN 6697, Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | Terminated | II | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-1122 | Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma | Terminated | II | >Brain [BN] | Other |
| NRG-HN003 | A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC) | Terminated | I | >Head and Neck [HN] | Head and Neck |
| RTOG-1114 | Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma | Terminated | II | >Brain [BN] | Other |
| RTOG-0522 | A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas | Terminated | III | >Head and Neck [HN] | Head and Neck |
| RTOG-9601 | A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the Prostate | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-1203 | A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP Study | Terminated | III | >Gynecologic [GY] | Other |
| RTOG-0129 | A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck Carcinomas | Terminated | III | >Head and Neck [HN] | Head and Neck |
| RTOG-0938 | A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer-RTOG CCOP Study | Terminated | II | >Genitourinary [GU] | Prostate |
| RTOG-0813 | Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients | Terminated | I/II | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-0912 | A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for The Treatment of Anaplastic Thyroid Cancer | Terminated | II | >Head and Neck [HN] | Head and Neck |
| RTOG-0521 | A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-0524 | A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder | Terminated | I/II | >Genitourinary [GU] | Bladder |
| RTOG-9910 | A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-0837 | Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma | Terminated | II | >Brain [BN] | Other |
| RTOG-0617 | A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer | Terminated | III | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-0526 | A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy | Terminated | II | >Genitourinary [GU] | Other |
| RTOG-0712 | A Phase II Randomized Study for Patients with Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery and Concomitant Chemoradiation by Either BID Irradiation plus 5-Fluorouracil and Cisplatin or QD Irradiation plus Gemcitabine Followed by Selective Bladder Preservation and Gemcitabine/Cisplatin Adjuvant Chemotherapy | Terminated | II | >Genitourinary [GU] | Bladder |
| RTOG-0424 | A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas | Terminated | II | >Brain [BN] | Lower Grade Glioma |
| RTOG-0913 | Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma | Terminated | I/II | >Brain [BN] | Other |
| RTOG-1014 | A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBRI) for Local Recurrence of Breast Carcinoma | Terminated | II | >Breast [BR] | Breast |
| RTOG-0436 | A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery | Terminated | III | >Gastrointestinal [GI] | Esophageal |
| RTOG-9804 | Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In Situ (DCIS) of the Female Breast | Terminated | III | >Breast [BR] | Breast |
| NRG-BR001 | A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases | Terminated | I | >Breast [BR] | Breast |
| RTOG-0839 | Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer | Terminated | II | >Lung [LU] | Non-small Cell Lung Cancer |
| GOG-0268 | A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary. | Terminated | II | >Gynecologic [GY] | Ovarian |
| NRG-GY011 | A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus | Terminated | I | >Gynecologic [GY] | Uterine Corpus |
| GOG-0210 | A Molecular Staging Study of Endometrial Carcinoma | Terminated | I | >Gynecologic [GY] | Uterine Corpus |
| GOG-0239 | A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0186H | A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin NSC # 729968, BB-IND #13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0214 | Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)
| Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0199 | Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
| Terminated | I | >Gynecologic [GY] | Ovarian |
| GOG-9923 | A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab(NSC #704865, IND #7921)and CTEP-Supplied Agent ABT-888(NSC #737664,IND# 77840)in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary PeritCancer | Terminated | I | >Gynecologic [GY] | Ovarian |
| RTOG-0631 | Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis | Terminated | II/III | >Symptom Management [CC] | Other |
| NSABP B-31 | A Randomized Trial Comparing The Safety And Efficacy Of Adriamycin And Cyclophosphamide Followed By Taxol (AC?T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC?T + H) In Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2 | Terminated | III | >Breast [BR] | Breast |
| NRG-GY008 | A Phase II Evaluation of Copanlisib BAY 80-6946 IND #130822, A Selective Inhibitor of PI3KCA, in patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations | Terminated | II | >Gynecologic [GY] | Uterine Corpus |
| NRG-GY002 | A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer | Terminated | II | >Gynecologic [GY] | Cervix |
| NRG-CC001 | A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases | Terminated | III | >Symptom Management [CC] | Other |
| GOG-0277 | A phase III randomized trial of gemcitabine (nsc# 613327) plus docetaxel (nsc# 628503) followed by doxorubicin (nsc# 123127) versus observation for uterus-limited, high-grade uterine leiomyosarcoma | Terminated | III | >Gynecologic [GY] | Uterine Corpus |
| GOG-0260 | A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072) (NCT# 00888615). | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0186K | A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-9926 | A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to Para-Aortic Lymph Nodes | Terminated | I | >Gynecologic [GY] | Cervix |
| NRG-GY001 | A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum | Terminated | II | >Gynecologic [GY] | Ovarian |
| RTOG-0627 | Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme | Terminated | II | >Brain [BN] | Other |
| NSABP BP-59 | Bone Marrow Analysis in Early-Stage Breast Cancer | Terminated | III | >Breast [BR] | Breast |
| NRG-GI001 | Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma | Terminated | III | >Gastrointestinal [GI] | Liver |
| RTOG-1306 | A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) | Terminated | II | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-0630 | A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the Extremity | Terminated | II | >Other [DT] | Sarcoma |
| RTOG-9402 | Phase III Intergroup Randomized Comparison of Radiation Alone Vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas | Terminated | III | >Brain [BN] | Other |
| RTOG-0621 | Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial | Terminated | II | >Genitourinary [GU] | Other |
| RTOG-9408 | A Phase III Trial of the Study of Endocrine Therapy used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the Prostate | Terminated | III | >Genitourinary [GU] | Prostate |
| RTOG-0915 | A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer | Terminated | II | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-0618 | A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer | Terminated | II | >Lung [LU] | Non-small Cell Lung Cancer |
| RTOG-0615 | A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal Cancer | Terminated | II | >Head and Neck [HN] | Head and Neck |
| RTOG-0131 | A Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligoastrocytomas | Terminated | II | >Brain [BN] | CNS Metastatic Disease |
| RTOG-9813 | A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) | Terminated | I/III | >Brain [BN] | Other |
| RTOG-9802 | A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma | Terminated | II/III | >Brain [BN] | Other |
| RTOG-0233 | A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabi | Terminated | II | >Genitourinary [GU] | Bladder |
| GOG-0184 | A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMA | Terminated | III | >Gynecologic [GY] | Uterine Corpus |
| GOG-9928 | A Phase I study of the safety of intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) administered in combination with pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer patients. The purpose of this studtermine the safety of EGEN-001 IP plus PLD treatment in platinum-recurrent ovarian cancer patients. | Terminated | I | >Gynecologic [GY] | Ovarian |
| GOG-9924 | A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240)in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | I | >Gynecologic [GY] | Ovarian |
| GOG-0280 | A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation | Terminated | II | >Gynecologic [GY] | Ovarian |
| GOG-0207 | A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, In The Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 | Terminated | II | >Gynecologic [GY] | Cervix |
| RTOG-0537 | A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia | Terminated | II/III | >Head and Neck [HN] | Head and Neck |
| NRG-GY029 | A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy
| Administratively Complete | II | >Gynecologic [GY] | Ovarian |
| NRG-LU006 | Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM) | Terminated | III | >Lung [LU] | Mesothelioma |
| NRG-CC004 | Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire in Women With Breast or Gynecologic Cancer | Terminated | II | >Symptom Management [CC] | Other |